Janssen begins phase 1b/2 clinical trial to assess multiple myeloma … – Pharmaceutical Business Review
|
Janssen begins phase 1b/2 clinical trial to assess multiple myeloma …
Pharmaceutical Business Review Janssen has commenced a phase 1b/2 clinical development program to assess JNJ-68284528 (developed based on Legend's LCAR-B38M), a chimeric … |
